Crossmark

Pharmacy stakeholder reports on ethical and logistical considerations in anti-opioid vaccine development

Published Online: 2021-03-25

Published Print: 2021-12

Authors

Wartenweiler, Vincent

Chung, Grace

Stewart, Amy

Wenthur, Cody http://orcid.org/0000-0001-6043-3842
Funding

Funding for this research was provided by:

National Center for Advancing Translational Sciences (UL1TR000427, UL1TR002373)
License Information

Text and Data Mining valid from 2021-03-25

Version of Record valid from 2021-03-25
More Information

Article History

Received: 22 June 2020

Accepted: 14 March 2021

First Online: 25 March 2021

Declarations

:

: This research was reviewed, evaluated, and approved by the UW-Madison Health Sciences Institutional Review Board (IRB), qualifying as exempt, minimal risk, human subject research. The need for signed written consent was waived by the UW-Madison Health Sciences IRB. Pursuant to the exempt research designation and IRB guidance, all participants were instead provided written and/or oral information regarding the purpose of the study, the procedures, risks, and confidentiality measures. This manuscript was prepared with reference to the Standards for Reporting Qualitative Research 21-item checklist [CitationRef removed].

: Not applicable.

: All authors have no competing interests to disclose.

Document is current